AdvisorShares Investments’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-20,543
| Closed | -$4.77K | – | 327 |
|
|
2024
Q4 | $4.77K | Buy |
20,543
+2,430
| +13% | +$6.79K | ﹤0.01% | 258 |
|
|
2024
Q3 | $68K | Buy |
18,113
+12,500
| +223% | +$71.8K | 0.01% | 257 |
|
|
2024
Q2 | $55.6K | Buy |
5,613
+1,998
| +55% | +$67.4K | 0.01% | 263 |
|
|
2024
Q1 | $273K | Buy |
3,615
+2,199
| +155% | +$290K | 0.05% | 217 |
|
|
2023
Q4 | $252K | Buy |
1,416
+1,254
| +774% | +$617K | 0.06% | 222 |
|
|
2023
Q3 | $114K | Buy |
162
+85
| +110% | +$364K | 0.03% | 214 |
|
|
2023
Q2 | $353K | Sell |
77
-27
| -26% | -$93.7K | 0.1% | 157 |
|
|
2023
Q1 | $276K | Buy |
104
+7
| +7% | +$20.5K | 0.09% | 173 |
|
|
2022
Q4 | $253K | Sell |
97
-25
| -20% | -$87.2K | 0.07% | 205 |
|
|
2022
Q3 | $484K | Buy |
122
+27
| +28% | +$106K | 0.13% | 99 |
|
|
2022
Q2 | $248K | Buy |
95
+2
| +2% | +$5.21K | 0.07% | 132 |
|
|
2022
Q1 | $301K | Buy |
93
+42
| +82% | +$181K | 0.05% | 134 |
|
|
2021
Q4 | $321K | Buy |
51
+38
| +292% | +$292K | 0.04% | 127 |
|
|
2021
Q3 | $125K | Buy |
+13
| New | +$112K | 0.02% | 165 |
|
AdvisorShares Investments's SEEL Position: Q1 2025 in Review
AdvisorShares Investments sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2025, closing a stake of 20,543 shares — an estimated $4.77K sold.
AdvisorShares Investments first reported a position in SEEL in Q3 2021 and held it in 14 quarters. The position peaked at $484K in Q3 2022. 0 funds tracked by Wall St. Rank hold SEEL as of Q1 2025.
- AdvisorShares Investments reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- AdvisorShares Investments sold 20,543 Seelos Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $4.77K.
- AdvisorShares Investments first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2021 and held it in 14 quarters.
- AdvisorShares Investments's Seelos Therapeutics, Inc. Common Stock position peaked at $484K in Q3 2022.
- 0 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2025.
Based on AdvisorShares Investments's 13F filing for Q1 2025, filed 13 May 2025.